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Abstract
Background: The TRIAL-STIM Study aims to assess the diagnostic performance, clinical outcomes and cost-
effectiveness of a screening trial prior to full implantation of a spinal cord stimulation (SCS) device.
Methods/design: The TRIAL-STIM Study is a superiority, parallel-group, three-centre, randomised controlled trial in
patients with chronic neuropathic pain with a nested qualitative study and economic evaluation. The study will
take place in three UK centres: South Tees Hospitals NHS Foundation Trust (The James Cook University Hospital);
Basildon and Thurrock University Hospitals NHS Foundation Trust; and Leeds Teaching Hospitals NHS Trust. A total
of 100 adults undergoing SCS implantation for the treatment of neuropathy will be included. Subjects will be
recruited from the outpatient clinics of the three participating sites and randomised to undergo a screening trial
prior to SCS implant or an implantation-only strategy in a 1:1 ratio. Allocation will be stratified by centre and
minimised on patient age (≥ 65 or < 65 years), gender, presence of failed back surgery syndrome (or not) and use
of high frequency (HF10™) (or not). The primary outcome measure is the numerical rating scale (NRS) at 6 months
compared between the screening trial and implantation strategy and the implantation-only strategy. Secondary
outcome measures will include diagnostic accuracy, the proportion of patients achieving at least 50% and 30% pain
relief at 6 months as measured on the NRS, health-related quality-of-life (EQ-5D), function (Oswestry Disability Index)
, patient satisfaction (Patients’ Global Impression of Change) and complication rates. A nested qualitative study will
be carried out in parallel for a total of 30 of the patients recruited in each centre (10 at each centre) to explore
their views of the screening trial, implantation and overall use of the SCS device. The economic evaluation will take
the form of a cost–utility analysis.
Discussion: The TRIAL-STIM Study is a randomised controlled trial with a nested qualitative study and economic
evaluation aiming to determine the clinical utility of screening trials of SCS as well as their cost-effectiveness. The nested
qualitative study will seek to explore the patient’s view of the screening trials, implantation and overall use of SCS.
Trial registration: ISRCTN, ISRCTN60778781. Registered on 15 August 2017.
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Background
Approximately 20% of the adult European population
has significant chronic pain, and 7–8% of the population
has chronic pain with neuropathic features [1–3].
Health-related quality of life is significantly poorer in
people with chronic pain than in those without [4], and
poorer in people with neuropathic pain than in those
with non-neuropathic pain [5]. In routine clinical care,
up to 50% of patients with neuropathic pain fail to ob-
tain pain relief from analgesic medicines [6].
In 2008, the National Institute for Health and Care
Excellence (NICE) recommended spinal cord stimulation
(SCS) as an effective and cost-effective treatment for se-
vere neuropathic pain refractory to medical management
conditional on a screening trial being conducted before
a final implant of SCS in every case [4, 7]. The evidence
for effectiveness and cost-effectiveness of such SCS
screening trials still remains unclear.
SCS screening trial and purpose
An SCS screening trial consists of the insertion of a wire
(lead) introduced into the epidural space of the spinal
cord through a needle puncture. The lead is then posi-
tioned to target the pain by passing current into the lead
from an external power source, generating paraesthesia
over the painful area. Pain coverage is expressed as a
percentage of the whole area of pain covered by the
paraesthesia. In patients where it is possible to achieve
≥ 80% coverage, the wire can be fixed to the spinal fascia
through an open procedure and tunnelled to exit
through the skin away from the incision. This technique
is known as a definitive trial because the same wire is
used later to attach to a battery if the trial is successful
[8]. In some cases the implantation of the lead may be
guided by anatomical landmarks rather than patient
feedback. In an alternative technique known as a tem-
porary trial, a wire is simply fixed to the skin at the site
of the epidural needle puncture of the back by sutures
or tape. The wire can be removed without the need for a
surgical intervention at the end of the trial but requires
a repeat implantation in the case of a successful trial.
Trials can last from a few minutes (‘on-table trial’) to a
few weeks (‘home trial’).
The screening trial period allows the patient to test
the efficacy of SCS therapy directly and specifically. An
expert panel defined a successful trial as the patient
reporting ≥ 50% pain relief during the trial with stable or
reduced pain medications, with at least stable levels of
daily activity [9].
Evidence for SCS screening trials as a predictor of long-
term success
SCS screening trials are recommended by consensus ex-
pert opinion and national guidance in many countries,
including the United Kingdom. However, the research
literature to date has not provided definitive evidence to
support the value of screening trials for SCS and in par-
ticular their ability to reliably predict the long-term suc-
cess of SCS therapy.
The PROCESS RCT trial randomised neuropathic pain
of failed back surgery syndrome (FBSS) compared SCS to
conventional medical management; 95% of the patients re-
ceiving SCS reported ≥ 50% pain relief at the screening
trial phase, but by contrast only 48% reported the same
outcome at 6-month follow-up [10]. Another RCT com-
pared SCS to reoperation in FBSS; 19/24 (80%) subjects re-
ported a successful screening trial, but only 9/15 (60%)
continued to report ≥ 50% pain relief at the 2-year
follow-up [11]. However, no pain outcome data were avail-
able for patients who failed the trial.
Similarly, the SENZA randomised trial comparing
high-frequency SCS to conventional SCS reported that
90/97 (92.8%) of subjects who trialled a higher frequency
of SCS and 81/92 (88.0%) subjects who were trialled
with traditional SCS were eligible for implantation [12].
By 12 months the figures for ≥ 50% pain relief dropped
to 78.7% and 51.3% respectively. Oakley et al. [13]
showed that 55% (18/33) of patients had ≥ 50% pain re-
lief at the 6-month follow-up compared to 75% in the
trial period. Screening trials have been shown to exclude
good candidates for SCS. Twelve patients who failed to
obtain ≥ 50% pain relief during an SCS screening trial
still received an implanted SCS device [13]. At
follow-up, a third of the patients reported pain relief
rates of 44–88%. The authors concluded that the screen-
ing trial is not the sole predictor of long-term success
but, again, did not assess pain outcomes in trial failures.
A retrospective study compared a 15-min on-table trial
to a 5-day home trial and found a 98% (53/54) success rate
for 15-min trials compared to 90% (47/52) for 5-day home
trials [14]. The authors concluded that since both methods
appeared to have equivalent predictive value for successful
long-term outcomes, home trials should be eliminated
based on increased therapeutic failures, greater risk of in-
fection and additional therapy costs.
Hypothesis and aims
We hypothesise that a no-SCS screening trial strategy
will be superior to an SCS screening trial and more
cost-effective. Specific aims of this study are to:
 compare the patient-related outcomes of an SCS
screening trial strategy to a no-trial implantation-
only strategy;
 determine the diagnostic performance (e.g.
sensitivity and specificity) of an SCS screening trial;
 compare the cost-effectiveness of a screening trial
strategy to a no-test implant-only strategy; and
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 assess the expectations and experiences of patients
for the use of an SCS screening trial.
Methods and design
Study design
The study is designed as a superiority, parallel-group,
three-centre RCT in patients with chronic neuropathic
pain with a nested qualitative study and economic evalu-
ation. Participants will be allocated in a 1:1 ratio to ei-
ther a strategy of a screening trial followed by SCS
implantation based on the screening trial result or an
SCS implantation-only strategy. Both groups will be
followed-up for 6 months post randomisation. Duration
for the main study protocol (i.e. start of recruitment to
last patient recruited completing all study procedures) is
expected to be 26 months. Patients’ participation within
the trial will last for 6 months following implantation.
The study design is summarised in Fig. 1.
Study population
One hundred adults (≥ 18 years) with chronic pain of
neuropathic origin will be recruited from three centres:
South Tees Hospitals NHS Foundation Trust (The James
Cook University Hospital); Basildon and Thurrock
University Hospitals NHS Foundation Trust; and Leeds
Teaching Hospitals NHS Trust.
Inclusion criteria
 Adults (≥ 18 years old) who are clinically considered
to be candidates for SCS as per NICE TA159 [15].
 Pain of neuropathic nature of an intensity of at least
5 as assessed on a numerical rating scale (NRS).
 Patient has persistent pain for more than 6 months
despite appropriate conventional medical and
surgical management including transcutaneous
electric nerve stimulation (TENS), acupuncture, oral
analgesic agents, cognitive behavioural therapy as
well as nerve blockade where appropriate.
 Satisfactory multidisciplinary assessment by a team
with expertise in delivering SCS therapy.
 Patient capable of providing informed consent.
Exclusion criteria
 Patient refusal to participate in the study.
 Presence of an ongoing pain condition considered by
the investigator to overshadow the neuropathic pain
condition to be treated with SCS.
 Current or previous treatment with an implanted
pain relief device.
 Current participation or planned participation in
other studies that may confound the results of this
study.
 Ongoing anticoagulation therapy, which cannot be
safely discontinued.
 Poor cognitive ability or lack of capacity.
 Unable to undergo study assessments or complete
questionnaires independently.
 Patient is pregnant or planning to become pregnant
during the course of the study.
Recruitment of patients
Patients will be recruited from the outpatient clinics of the
three participating sites. Patients who are scheduled to
have a spinal cord stimulator trial will be approached and
given a Patient Information Sheet to take home to read.
Informed consent will be obtained from suitable patients
following a reasonable period of time by one of the
Principal Investigators or delegated individuals at each site
following International Conference on Harmonisation/
Good Clinical Practice (ICH/GCP) guidelines [16].
Interventions
Screening trial and implantation strategy (usual care)
Patients randomised to this arm will receive a screening
trial. A screening trial will consist of passage of either an
external or internalised tunnelled SCS lead or leads at-
tached to an external stimulator as per the centre’s rou-
tine practice. Those patients who have a successful
screening trial will receive an implantable neurostimula-
tion system while unsuccessful patients would not re-
ceive such an implant. Taking into consideration the
RCTs included in the clinical evidence section of NICE
TA159 [15], a successful screening trial will be defined
as ≥ 50% pain relief and satisfactory on-table paraesthe-
sia coverage (i.e. ≥ 80%) of the pain area, reduction in
pain medications or improved quality of life and func-
tion, and successful location of leads at the anatomical
target for paraesthesia-free therapies [10, 17]. Patients
with an unsuccessful screening trial will not be im-
planted but all patients will continue follow-up to 6
months. Successful trial patients will go on to have the
implantable pulse generator (IPG) implanted on a separ-
ate occasion.
Implantation-only strategy
In the implantation-only strategy group, all patients with
satisfactory on-table paraesthesia coverage (i.e. ≥ 80%) of
the pain area and no dislike of sensations [18], and satis-
factory anatomical lead location for paraesthesia-free de-
vices, would receive a permanent implant in one surgery.
Outcome measures
Patient outcomes will be collected at clinic visits at base-
line (pre randomisation) and 6 months post randomisa-
tion unless otherwise stated.
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Primary outcome
The primary outcome measure is the comparison be-
tween pain NRS at 6 months between the screening trial
and implantation strategy and the implantation-only
strategy [19].
Secondary outcomes
Secondary outcome measures include: the proportion of
patients achieving at least 50% and 30% pain relief at 6
months as measured on the NRS [19], health-related
quality of life (EQ-5D) [20], function (Oswestry Disabil-
ity Index) [21], patient satisfaction (Patients’ Global Im-
pression of Change) [22] and complication rates.
A qualitative study using semi-structured interviews
will be carried out in parallel for a total of 30 of the pa-
tients recruited in each centre (10 at each centre) to
explore their views of the screening trial, implantation
and overall use of the SCS device.
Self-reported information on healthcare utilisation and
non-NHS costs will be collected from participants using a
standardised questionnaire to include management of ad-
verse events (AEs), interventions, investigations, medica-
tion, inpatient hospitalisations, A&E, reprogramming visits
and other healthcare-related visits, plus out-of-pocket
costs and absences from work.
Data collection and visits
Along with data collection at baseline, all of the outcomes
will be sought through routine pain clinic attendances at 3
and 6 months. All unscheduled visits will be recorded in a
log. The type of data collected during these visits is listed
in Fig. 1 (SPIRIT diagram and Additional file 1).
STUDY PERIOD
Enrolment Allocation Post-allocation Visits
Procedure Baseline 
Visit
Standard 
Trial/ 
On-
Table 
Trial
Permanent 
Implant 
(Standard 
Trial only)
1 
Month 
Visit
3 
Month 
Visit
6 
Month 
Visit
Informed Consent X
Inclusion and exclusion 
criteria check
X
Demographics X
Medical and Surgical 
History
X
Pain History X
Pregnancy test (Females of 
childbearing potential only)
X
Multidisciplinary assessment X
EQ-5D-5L Questionnaire X X X
PGIC Questionnaire X X
Oswestry Disability Index 
Questionnaire
X X X
Numeric Rating Scale X X X
Healthcare Utilisation X X X
Work Status, absence from
work and out of pocket 
expenses
X X X
Satisfaction Questionnaire X X
Randomisation to Screening 
trial
X
Randomisation to Qualitative 
Interview
X
SCS Implant X (X)
Skin to skin time X (X)
SCS technical data (Lead 
data, Model No)
X (X)
Qualitative Interview (if 
randomised)
X X
Adverse Event assessment X (X) X X
Pain and Concomitant 
medication check
X X (X) X X
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram. EQ-5D-5L five-level EuroQol-5D, PGIC Patients’ Global
Impression of Change, SCS spinal cord stimulation
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Baseline visit
Patients who have been identified as potential partici-
pants will be sent a patient information sheet to read
prior to the baseline visit. An MDT assessment will have
been undertaken and the patient deemed suitable for
SCS prior to the baseline visit. In the clinic, full written
informed consent will be taken by the Principal Investi-
gator or sub-investigator at the site or a suitable person
as per the Delegation Log. Informed consent will be
obtained during this visit.
Implant visit
Subjects who are randomised to the screening trial and
implantation strategy will undergo two procedures as
per usual clinical practice with a trial procedure and, if
successful, a permanent implant in a second procedure.
Details of the trial procedure will be as per usual clinical
practice at the centre. Subjects who are randomised to
the implantation-only strategy will undergo one proced-
ure with the trial and permanent implant in one proced-
ure. Wound care and management of the trial leads will
be conducted as per the centre’s usual clinical practice
regardless of trial randomisation.
One-month telephone interview following permanent
implant (optional)
Subjects who have consented to undergo the qualitative
interview and who have been randomised to do so will
undergo a second interview.
Three-month and 6-month (end of study) visit following
permanent implant
All patients will attend the clinic for the 3-month and
6-month appointments. Following the 6-month visit the
patient will exit the study and be passed back to usual
care within the pain clinic for ongoing management for
the spinal cord stimulator.
Data collection and follow-up for withdrawn subjects
If a patient withdraws from the trial treatment, then they
will be followed up wherever possible and data collected as
per protocol until the end of the trial. The only exception
to this is where the patient also explicitly withdraws con-
sent for follow-up. Subjects who withdraw from the study
will be initially invited to attend a follow-up appointment
by letter. In the case of no response, the subject will be
contacted by telephone twice over a 2-week period.
Sample size determination
We plan to recruit and randomise a total of 100 patients
(50 per group) in order to detect a statistically significant
and clinically meaningful between-group difference using
our primary outcome based on an intention-to-treat
analysis. A sample size of 50 patients in the implantation
strategy arm will determine our precision to estimate the
specificity and sensitivity of the SCS screening test.
Assuming that the SCS screening trial has little or no
clinical utility we would hypothesise superiority of the
no-screening strategy over the screening strategy. For a
pain NRS (0–10), IMMPACT proposes a minimal clinic-
ally important difference (MCID) of 2 points [19]. Based
on a typical pain NRS standard deviation of 2.5 seen in
previous SCS RCTs [10, 17, 23], at 90% power and 5%
alpha, and a worst-case attrition rate of 30% [10, 17, 23],
we will require a total of 50 patients recruited per group.
Given the lack of previously published sensitivity and
specificity values for the SCS screening test, Table 1 pre-
sents our margins of error of estimation (width of the
95% confidence interval (CI)) based on 50 patients in
the implantation strategy arm across a range of possible
values of diagnostic performance.
Randomisation
Randomisation will be achieved by means of a
password-protected web-based system developed and
maintained by Exeter Clinical Trials Unit (ExeCTU). Once
the patient has completed the screening interview and
baseline data collection interview, the researcher will ac-
cess the randomisation website using a unique username
and password. The website will require entry of the study
site and participant age before returning the participants’
unique randomisation number and allocation (Engager
Intervention or Control). Allocation will be stratified by
centre and minimised on patient age (≥ 65 or < 65 years),
gender, presence of FBSS or not and use of high frequency
(HF10™) or not. Allocation concealment will be maintained
by only revealing allocation of each participant to the study
manager following completion of written informed con-
sent and baseline outcomes.
It is not possible to blind patients, clinicians or re-
searchers to group allocation. However, to minimise as-
sessment bias we will seek to blind the researchers
undertaking outcome assessment and the data analysts
to group allocation by masking them from group alloca-
tion. Each site team consists of a blinded and an un-
blinded assessor. These do not cross roles or exchange
information. Database entries are also clearly divided
into blinded and unblinded sections with no potential
Table 1 Margins of error of estimation based on 50 patients in
the implantation strategy arm
Margin of error Sensitivitya (%) Specificitya (%)
100% 8.9 30.9
80% 26.6 53.3
60% 31.8 61.6
40% 31.8 61.6
aAssuming 40/50 patients have ≥ 50% pain relief at 6 months
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for crossed data entry since blinded assessor login only
allows access to a limited set of data.
All sites have clinical experience with both SCS im-
plantation after the extended trial and immediate SCS
implantation after the on-table trial. Research and clin-
ical teams are equipoised as regards the outcome of this
clinical trial.
Statistical analysis
Diagnostic performance
Analyses will be conducted and reported in accord with
STARD recommendations [24]. Cross-tabulation will be
used to report the SCS test results (fail versus pass) ver-
sus SCS pain relief (≥ 50% versus < 50%) at 6-month
follow-up. Sensitivity will be determined as the percent-
age of participants with ≥ 50% pain relief at 6 months
who pass the test, and specificity as the percentage of
participants with < 50% pain relief who fail the test. Posi-
tive and negative likelihood ratios will be also calculated
and reported. All results will be reported with 95% CIs.
Comparison of effectiveness
Analyses will be conducted and reported in accord with
CONSORT recommendations [25]. We will closely moni-
tor the process of data collection during the trial and pro-
vide a flow diagram summarising, by group, the numbers
approached, recruited, randomised, followed up/lost to
follow-up and outcome completion (Fig. 2). Primary ana-
lyses will be conducted on an intention-to-treat basis (i.e.
according to randomised group) and to compare primary
and secondary outcomes at 6-month follow-up between
randomised groups on those with complete datasets. Out-
comes will be compared using linear regression methods
adjusting for baseline outcome scores and stratification/
minimisation variables. Additional secondary analyses will
be performed. Primary and secondary outcomes will be
compared at 3 months as already described. The influence
of missing data will be investigated using sensitivity ana-
lyses that make different assumptions, such as “best” and
“worst” case scenarios depending on outcome type, as well
as using multiple imputation methods. Exploratory ana-
lyses using interaction terms will be used to assess the po-
tential subgroup effects according to stratification and
minimisation variables.
No interim or subgroup analyses are planned. All ana-
lyses will be undertaken using STATA v.14. A detailed
statistical analysis plan will be prepared before any data
analysis is conducted and agreed with the Trial Steering
Committee (TSC)/Trial Management Group (TMG).
The study team will have access to the final trial dataset.
Economic evaluation
An economic evaluation will be carried out to estimate the
cost-effectiveness of a screening trial and implantation
strategy versus an implantation-only strategy. Health-
care resource utilisation (e.g. management of AEs, in-
terventions, investigations, medication, inpatient
hospitalisations, A&E and other healthcare-related
visits, plus out-of-pocket costs and absences from
work) will be collected for each patient during the
study follow-up period using data collection methods
which have been successfully adopted by the applicants
in previous studies [10, 23]. Resources required for the
specific screening trial and implantation interventions
will be recorded within the trial.
Items of resource use will be costed using national
averages obtained from national sources (such as the
Personal Social Services Research Unit, the British
National Formulary and NHS reference cost databases)
[26–28]. Cost components will be combined to derive
total patient-level costs for the NHS. In addition,
non-NHS costs such as productivity loss due to absence
from work or patient out-of-pocket expenses will also be
quantified to provide a full picture of how the strategies
being compared will affect the financial burden imposed
by the condition on both the NHS and the patients.
Generic health-related quality of life (HRQoL) data will
be collected using the EQ-5D-5L instrument. Both
resource utilisation (costs) and the EQ-5D-5L will be
collected at each follow-up visit. A within-trial cost con-
sequence analysis will be carried out to estimate mean
resource utilisation, costs, EQ-5D scores and total
quality-adjusted life-years (QALYs) in each group, to-
gether with relevant measures of sampling uncertainty.
QALYs will be calculated using the area under the curve
approach, with regression-based adjustment for baseline
EQ-5D score. The economic evaluation will take the
form of a cost–utility analysis, to calculate the cost per
additional QALY gained. Base-case analyses will be con-
ducted from the NHS perspective, with additional ana-
lyses from the societal perspective. Deterministic
sensitivity analysis will be undertaken to explore the ro-
bustness of the results to plausible variations in key as-
sumptions and variations in the analytical methods used.
In order to account for uncertainty, probabilistic sensitivity
analysis (PSA) will also be undertaken using bootstrapping
and the bootstrapped cost–effect pairs will be graphically
presented on a cost-effectiveness plane. Cost-effectiveness
acceptability curves will be constructed to show the prob-
ability that the intervention is cost-effective for specific
thresholds of cost per QALY gained.
A two-stage economic model will also be developed
with a decision tree reflecting the outcomes of the first 6
months and reproducing the observed TRIAL-STIM
Study outcomes. After this 6-month period, a Markov
“state transition” model will then extrapolate the evolu-
tion of patient outcome and costs over a period of
15 years. The model will be populated with data from
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the trial itself and previously published research. Again,
extensive deterministic and probabilistic sensitivity ana-
lysis will be undertaken.
Qualitative analysis
All subjects will be consented to take part in both the
RCT and the optional qualitative study at the outset. A
semi-structured telephone interview will be carried out
with 30 patients recruited by purposive sampling (among
those consenting) at three sites (at baseline and 1 month
post implantation). Baseline interviews will explore the
impact of pain on daily living, thoughts and
understanding of the screening trial and implantation
only and expectations of the spinal cord stimulator.
One-month follow-up interviews will revisit thoughts
and understanding of the spinal cord stimulators, expec-
tations and explore their overall experience of the SCS
device. Ten patients will be recruited from each centre,
five from each treatment arm. Open-ended questions
will be used to allow patients to express their own view-
points. The interviews will be audio recorded and tran-
scribed. Data will be analysed using thematic analysis
[29, 30], facilitated by NVivo qualitative analysis soft-
ware. The data will be interpreted as follows:
Fig. 2 Consolidated Standards Of Reporting Trials (CONSORT) flow diagram
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1. themes emerging for the total patient group; and
2. themes emerging for the patients grouped by arm
of the study (screening trial/implantation only).
In addition, participants will be asked to reflect and ex-
plore their experience of being in the study and evaluate
things that went well, as well as to provide suggestions for
changes and to complete a purpose-designed 5-point scale
indicating their overall preference in relation to the two
options (screening trial/implantation only).
Trial management and quality assurance
Trial Steering Committee
The trial is guided by a group of respected and experi-
enced pain consultants as well as research personnel. The
steering committee is chaired by Dr Richard North (RN).
The membership of the groups will consist of the
Chief Investigator (SE), RN as an independent member,
study statistician (RST), independent statistician (Profes-
sor Alan Batterham, AB), health economics study team
(SJ and RD), psychologist representing qualitative inter-
views (RC), study manager (MB) and a Patient and Pub-
lic Involvement (PPI) representative as a lay person (JE).
Video/teleconference meetings will be held at regular
intervals determined by need but not less than twice a
year. Routine business is conducted by email, post or
teleconferencing.
The Steering Committee, in the development of this
protocol and throughout the trial, will take responsibil-
ity for:
 major decisions such as a need to change the
protocol for any reason;
 monitoring and supervising the progress of the trial;
 reviewing relevant information from other sources;
 reviewing data management and ethical
arrangements; and
 informing and advising on all aspects of the trial.
Trial Management Group
The administration will be overseen by a TMG chaired
by the Chief Investigator.
Membership of the TMG will include the principal in-
vestigator (PI) on all three sites (AG, ST and GB), mem-
bers of the qualitative studies team (RC/HS), members
of the health economics team (RD/SJ), study statistician
(RST), study manager (MB) and study nurses from all
study sites.
The TMG will meet at monthly intervals initially at set
up and then 3-monthly either face to face or by tele/vid-
eoconferencing where possible.
The trial and day-to-day, non-clinical aspects will be
coordinated by the Study Manager (MB) based at The
James Cook University Hospital. All clinical coordination
of the trial will be the responsibility of the Chief Investi-
gator. The Chief Investigator will assume responsibility
for the overall management and conduct of the trial, and
AG, ST and GB will act as PI for the Middlesbrough,
Basildon and Leeds sites respectively. Each PI will as-
sume responsibility for leading the trial in their centre.
The trial office team will:
 distribute the case report forms (CRFs) to
participating centres;
 monitor the collection of data, process data, seek
missing data and clarify ambiguous data;
 ensure the confidentiality and security of all trial
forms and data;
 liaise with Exeter CTU regularly regarding data
entry and randomisation;
 coordinate any interim and main analyses; and
 organise Steering Committee and Collaborator
meetings.
The trial office will receive and check completed CRFs
via the postal service as well as the online database.
Upon receipt, data forms will be checked for complete-
ness and a sample checked against the online study data-
base. Data will be downloaded onto a master chart,
which will be communicated to the study statistician.
Patient confidentiality will be maintained at every
stage and we will comply with the Data Protection Act
(1998).
Any further amendments to the protocol will be
submitted to a properly constituted Research Ethics
Committee (REC) for approval of the study conduct.
Safety monitoring
An AE is defined as any untoward medical occurrence
in a patient during or following administration of an in-
vestigational product/procedure and which does not ne-
cessarily have a causal relationship with treatment. An
AE can therefore be any unfavourable and unintended
sign (including an abnormal laboratory finding), symp-
tom or disease temporarily associated with the use of
the trial device, whether or not considered related to the
trial device. PIs will assess all AEs regarding their rela-
tionship to SCS. The SCS-related AEs include but are
not limited to: occurrence of redness, tenderness or
other sign of infection over the SCS implant site; obser-
vation of collections or other abnormalities over implant
sites; shifting of the site of paraesthesia from the site ori-
ginally intended, causing reduction in pain relief with in-
ability to shift paraesthesia to the original position using
programming; lead migration, either vertical or medio-
lateral; pain reports over implant sites; and patient re-
ports of cessation of paraesthesia not remedied by
reprogramming of the device. All adverse events will be
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followed until they have abated, or until a stable situ-
ation has been reached. Depending on the event,
follow-up may require additional tests or medical proce-
dures as indicated, and/or referral to the general phys-
ician or a medical specialist.
All clearly related signs, symptoms and abnormal diag-
nostic procedures or results will be recorded in the
source document and grouped under one diagnosis. All
adverse events occurring during the study period will be
recorded. The independent members of the Steering
Committee will be presented with the safety data prior
to the Steering Group Meetings.
The trial is subject to the audit arrangements of the
National Institute of Health Research (NIHR).
Dissemination policy
For primary result publications, the study team will form
the basis of the writing committee and will also advise
on any related publications from the trial. Primary publi-
cations will include co-investigators as named authors or
as part of a group authorship. In general, any related
publications should include the principal investigators,
lead researchers, statisticians and site staff as named au-
thors; however, this is at the discretion of the writing
committee.
Discussion
SCS has been tested against various control therapies in
the management of neuropathic pain of FBSS as well as
painful diabetic neuropathy and Complex Regional Pain
Syndrome (CRPS) [10, 17, 31]. All studies have imple-
mented a screening trial prior to implantation of the
final permanent components of the therapy. While gen-
erally recommended by most guidelines [15, 32], none of
the guidelines present an evidence-based rationale for
screening trials.
Pros and cons of screening trials
Screening trials give patients the opportunity for a short
period of experiencing SCS therapy and allow them to ex-
perience the sensation generated by SCS and its inter-
action with body movements. This also allows patients
and physicians a baseline evaluation of the pain relief and
current consumption, which influence the choice of bat-
tery implanted. However, screening trials require duplica-
tion of procedures, thereby consuming more healthcare
resources. In a recent RfPB-funded study the applicants
adopted a no-screening trial policy with average on-table
total implant time of 111 min [23]. By contrast, the normal
screening trial surgery duration averages 90 min and pulse
generator implant surgery averages 60 min [33].
Moreover, prolonged SCS screening trials expose pa-
tients to a higher risk of infection due to bacterial colon-
isation of the wire skin exit site. Longer trials of up to
15 days have been associated with an infection rate of
7.5% compared to an average infection rate in the same
department of 2.8% [8]. As most SCS infections require
device removal this is an expensive as well as an incon-
venient complication. We also found screening trials to
be associated with severe and prolonged surgical pain,
calling into question a patient’s ability to judge the im-
pact of SCS on their original pain.
In conclusion, published studies to date call into ques-
tion the predictive value of screening trials. While screen-
ing trials allow patients to experience first-hand the effects
of SCS therapy before deciding to receive a permanent im-
plant, screening trials are costly, require procedure dupli-
cation, are associated with increased risk of infection and
may not appropriately represent therapeutic long-term
outcomes. The current NICE recommendation [15] that
all candidates for SCS undergo screening trials is largely
based on expert opinion rather than firm evidence.
A number of studies have examined the predictive
value of screening trials in predicting long-term outcome
of SCS therapy, but none with an appropriate design or
adequate power [14, 34].
Weinand et al. [14] conducted a retrospective case series
of 54 patients. All patients had an acute 15-min on-table
trial followed by an externalised approximately 5-day trial
with a mean follow-up of 9.4 ± 1.5 months. The screening
trial success rate was reported at 98% in acute screening
and 90% in prolonged screening. The authors concluded
that acute and prolonged SCS screening appear to have
equivalent predictive value for successful long-term SCS
control of chronic low back and/or lower extremity pain.
These preliminary results suggest potential justification for
eliminating prolonged and retaining acute (intraoperative)
SCS screening for selection of permanent SCS implantation
candidates. The investigators found no clear difference be-
tween acute on-table trials and prolonged outpatient trials
and concluded that on-table acute trials were more
cost-effective. Moriyama et al. [34] conducted a prospective
cohort of 55 patients of various pain aetiologies implanted
with SCS and followed up for 6 months. They reported a
screening trials success rate of 61.8% (34/55), reported the
factors predicting a positive response to include increased
paraesthesia coverage, female gender and disorders of per-
ipheral vs central nervous system, and reported screening
trial sensitivity of 84.8% and specificity of 70% (14/20).
Given that both of these studies reported such a wide
margin of screening trial success and included a small
sample size, we believe that the proposed TRIAL-STIM
Study is fully justified clinically and economically.
Trial status
The TRIAL-STIM Study began recruitment in June
2017. The trial is scheduled to end recruitment in
January 2019.
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